India Pharma Q1 FY27: Marksans PAT Surges 174%, Natco Brazil Up 180% as Himatsingka Pivots Strategy

India's Q1 FY27 pharma and textile earnings season highlighted Marksans Pharma's 173.9% profit surge and Natco Pharma's 34% normalized profit jump, while Himatsingka Seide pivoted strategically and PAVmed narrowed losses.

• Marksans Pharma (BOM:524404) Q1 FY27: revenue +35.6%, PAT +173.9% on UK/Europe strength
• Natco Pharma (BOM:524816) Q1 FY27: normalized profit +34% QoQ despite revenue dip from lower lenalidomide
• Himatsingka Seide unveils 'Himatsingka 2.0' pivot to yarn/fabric amid US home textile headwinds

Marksans Pharma delivered the standout results in the batch, with PAT (profit after tax) surging 173.9% year-over-year as the company's UK and European generic pharmaceutical operations drove exceptional growth. Revenue expanded 35.6%, but the profit growth significantly outpaced revenue, implying operating leverage and mix improvement toward higher-margin products. Marksans has been building its presence in the UK generic market for several years, and the Q1 FY27 results suggest that investment is now paying off at scale.

Natco Pharma's results required more nuanced interpretation. Reported revenue declined due to lower sales of lenalidomide — a high-value cancer drug where generic competition has been eroding price realizations — but the company's normalized profit (stripping out the lenalidomide comparison effect) jumped 34% quarter-over-quarter, with a 180% surge in Brazil contributing materially. Brazil's pharmaceutical market is growing rapidly, and Natco's traction there provides geographic revenue diversification that reduces dependence on any single product cycle.

Himatsingka Seide's 'Himatsingka 2.0' transformation announcement was the most strategically significant development in the cluster. The company is pivoting its product mix toward new yarn and fabric solutions to offset weakness in US home textile exports — a segment under pressure from import competition and moderating US consumer spending on household goods. PAVmed, a US-listed medical device company also covered in the batch, reported a significantly reduced net loss and meaningful progress on its VARIS commercial launch at Ohio State University.

Synthesized from 4 source(s).